441 Live Oak Drive, Mill Valley, CA 94941, USA www.protexatherapeutics.com

Protexa Therapeutics

Protexa Therapeutics develops proprietary pharmaceutical products based on a platform of TGF-beta production stimulators, discovered within Cambridge University.  Protexa’s lead product is a proprietary fixed-dose combination of droloxifene and clopidogrel, being developed for the treatment of cardiovascular disease, and in particular acute coronary syndromes.

The company has recently completed the final pieces of preclinical development on its lead programme, and is actively seeking a series A investment to initiate clinical development.

Protexa Therapeutics is based in the San Francisco bay area in the USA.